The Relationship between Interleukin-18 Polymorphisms and Allergic Disease: A Meta-Analysis

Table 1

Characteristics of studies included in the present meta-analysis.

Studies	Year	Country	Ethnicity	Type	Source of controls	Sample size	SNP studied	Genotyping method	HWE
Harada et al. [31]	2009	Japan	Asian	AA	PB	453/719	−607C/A; −137G/C	Taqman	0.29; 0.48
Heinzmann et al. [32]	2004	German	Caucasian	AA	PB	230/269	−607C/A; −137G/C	Taqman	0.68; 0.17
Birbian et al. [33]	2013	Indian	Asian	AA	PB	410/414	−137G/C	ARMS-PCR	<0.001
Yang et al. [40]	2009	China	Asian	AA	PB	102/100	−607C/A; −137G/C	PCR-SSP	0.08; 0.74
Imboden et al. [34]	2006	Swiss	Caucasian	AA	HB	530/5204	−137G/C	Taqman	0.37
Lachheb et al. [38]	2008	Tunisia	Caucasian	AA	HB	105/112	−607C/A	PCR-RFLP	0.002
Pawlik et al. [35]	2007	Poland	Caucasian	AA	PB	231/305	−607C/A; −137G/C	Allele-specific PCR	0.75; 0.08
Sebelova et al. [10]	2007	Czech	Caucasian	AR	HB	539/312	−607C/A; −137G/C	PCR-RFLP	0.06; 0.80
Shin et al. [37]	2005	Korea	Asian	AA	PB	438/149	−607C/A; −137G/C	PCR-sequencing	0.14; 0.36
Wu et al. [36]	2012	China	Asian	AA	PB	120/120	−607C/A; −137G/C	PCR-SSP	0.05; 0.40
Chen [39]	2008	China	Asian	AA	HB	82/78	−607C/A; −137G/C	PCR-SSP	0.66; 0.89
Ibrahim et al. [41]	2012	Egypt	Caucasian	AD	HB	25/25	−137G/C	PCR-RFLP	0.10
Trzeciak et al. [42]	2010	Poland	Caucasian	AD	PB	67/46	−137G/C	ARMS-PCR	0.07
Luo et al. [45]	2008	China	Asian	AD	PB	82/100	−607C/A; −137G/C	PCR-SSP	0.62; 0.76
Izakovicova et al. [49]	2010	Czech	Caucasian	Allergic disorder	PB	633/325	−607C/A; −137G/C	Taqman	0.09; 0.71
Lee et al. [46]	2006	China	Asian	AR	HB	160/166	−607C/A	PCR-RFLP	<0.001
Ming et al. [47]	2011	China	Asian	Drug allergy	HB	606/614	−607C/A; −137G/C	PCR-sequencing	0.07; 0.09
Osawa et al. [44]	2007	Japan	Asian	AD	PB	21/100	−607C/A; −137G/C	PCR-sequencing	0.88; 0.48
Kim et al. [48]	2011	Korea	Asian	Drug allergy	PB	275/196	−607C/A; −137G/C	SNaPshot	0.84; 0.17
Kato et al. [43]	2009	Japan	Asian	AD	HB	160/104	−137G/C	PCR-RFLP	0.11
Torres et al. [50]	2010	Spain	Caucasian	Henoch-Schönlein purpura	PB	62/200	−607C/A; −137G/C	Taqman	0.05; 0.10

AA, allergic asthma; AD, allergic dermatitis; AR, allergic rhinitis; PB, population-based controls; HB, hospital-based controls; HWE, Hardy-Weinberg equilibrium; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SSP, sequence-specific primers.